BioMedNewsBreaks

FridayFeb 05, 2021 10:11 am

BioMedNewsBreaks – Intec Pharma Ltd. (NASDAQ: NTEC) Featured by M-Vest

Intec Pharma (NASDAQ: NTEC), a clinical-stage biopharmaceutical company, was recently highlighted as a featured company by M-Vest. The business description reads, “Intec’s strategy is to leverage its proprietary delivery technology to improve the properties of known/approved compounds. Intec also plans to work in collaboration with biotechnology and pharmaceutical companies to develop novel delivery systems for their proprietary drugs, including existing compounds undergoing lifecycle management.” For more details, visit https://ibn.fm/WUpyI About Intec Pharma Ltd. Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill(R) platform technology. The company's Accordion Pill is an oral drug…

Continue Reading

FridayFeb 05, 2021 9:21 am

BioMedNewsBreaks – Adial Pharmaceuticals Inc (NASDAQ: ADIL) Featured by M-Vest

Adial Pharmaceuticals (NASDAQ: ADIL), a clinical-stage biopharmaceutical company, was recently highlighted as a featured company by M-Vest. The update reads, “Adial has created an investigational attendant diagnostic biomarker blood test for the genetic screening of patients with certain biomarkers that, as reported in the American Journal of Psychiatry (Johnson, et. al. 2011 & 2013), Adial believes make patients more likely to benefit from treatment with AD04. Adial’s strategy is to integrate pre-treatment genetic screening into AD04’s label to create a patient-specific treatment in one integrated therapeutic offering. Adial’s goal is to develop a genetically targeted, effective and safe product candidate…

Continue Reading

ThursdayFeb 04, 2021 3:00 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) on the Verge of Changing History with Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, has set sights on an encouraging future for glioblastoma patients with its upcoming Phase 2 trial of Berubicin. The article detailing this groundbreaking news quoted the company’s CEO John Climaco as saying, “Anthracyclines as a class of chemotherapy have been used for over 60 years to treat a variety of cancers… However, historically, anthracyclines have never been used to treat primary or metastatic brain cancers because scientists could not demonstrate that anthracyclines were able…

Continue Reading

ThursdayFeb 04, 2021 1:13 pm

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Harnesses Blue Light, Innovative Technology for Cancer Imaging

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is harnessing the virtues of blue light in a health-enhancing way. By utilizing the company’s proprietary i/Blue Imaging (TM) System with a contrast agent, surgeons will be able to better visualize the parameters of cancers and develop the appropriate response strategy. Imagin is developing its platform for use in bladder cancer surgery. It relies on Cysview, a drug that rapidly infiltrates cancer cells and causes them to glow bright pink under blue light. Cysview is administered just before surgery and the blue light is used endoscopically to locate and examine…

Continue Reading

ThursdayFeb 04, 2021 11:16 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Joins Millions to Recognize World Cancer Day

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it joins with millions of healthcare advocates around the world in support of World Cancer Day. The designation seeks to raise awareness, elevate public understanding of the global cancer burden, promote greater equity and ensure that cancer control continues to be a priority in the world health and development agenda. “At Genprex, our primary focus is on the patients and communities we serve. Toward that end, we are relentless in our pursuit to bring innovative and life-saving oncology treatments to patients suffering with…

Continue Reading

ThursdayFeb 04, 2021 9:16 am

BioMedNewsBreaks – Capricor Therapeutics Inc. (NASDAQ: CAPR) Featured by M-Vest

Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company, was recently highlighted as a featured company by M-Vest. The business description reads, “CAP-1002 consists of allogeneic cardiosphere-derived cells, or CDCs, a unique population of cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 200 human subjects across several clinical trials.” For more details, visit https://ibn.fm/Ejtce About Capricor Therapeutics Inc. Capricor Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization…

Continue Reading

TuesdayFeb 02, 2021 1:44 pm

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Ranked as Buy in Litchfield Hills Recent Analyst Report

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has been rated as a “Buy” in the first analyst coverage report released by equity research firm Litchfield Hills Research LLC. POAI was listed as a “Buy” under the report’s three-tiered (buy, hold, sell) rating system. Litchfield Hills Research strictly follows FINRA standards for quality and objectivity, and the research firm has certified that the publication is compliant with FINRA research rules 2241, 3110. In addition, Litchfield confirmed that the report has been reviewed by a supervisory senior analyst and is…

Continue Reading

TuesdayFeb 02, 2021 10:49 am

BioMedNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Trio of Upcoming Investment, Industry Events

MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops, is involved in several upcoming investment and industry conferences, and has released information regarding three upcoming investment and industry conferences in which it will be participating. The events include CSE Tech Tuesdays, a virtual public company showcase, which is today at 4:15 p.m. ET; World Agri-Tech Innovation Summit, a virtual innovation event slated for March 9–10; and the Banff Capital Conference, scheduled for March 12–14. The company noted that these events are part of MustGrow’s awareness initiatives. The…

Continue Reading

TuesdayFeb 02, 2021 10:38 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Marketing VP Authors Article on Increasing Need for Disposable Technologies

Brain Scientific (OTCQB: BRSF) vice president of marketing Stuart Bernstein has authored a DotMed Healthcare Business News article titled “COVID’s influence on neurology drives need for disposable technologies.” In the article, Bernstein notes both time management and infection control as key factors in the growing need for disposable technologies. The article states that headsets with pre-gelled and fixed electrodes could reduce the time-consuming electrode placement process. In addition, the article explains that commercially available EEG headsets that pair with encephalographs and amplifiers of EEG signals can deliver results in an average of 20 minutes. These time-saving measures mean that doctors could…

Continue Reading

TuesdayFeb 02, 2021 10:26 am

BioMedNewsBreaks – Trxade Group Inc. (NASDAQ: MEDS) to Postpone February Virtual Road Show

Trxade Group (NASDAQ: MEDS), an integrated drug-procurement, delivery and healthcare platform, has announced that it will postpone its upcoming virtual road show. Trxade had previously announced that the road show event would be held Wednesday, Feb. 3, 2021, at 11 a.m. ET. The company, which operates across the United States in all 50 states, will reschedule the event and announce the new date and time. Trxade Group is committed to its mission of making healthcare services affordable and accessible. “The virtual roadshow will be postponed to a later date, which will be announced via press release accompanied by a webcast link…

Continue Reading